low systemic absorption technology

[thechamp]

Has any body been able to contact these people ??

[hellouser]

We really need to push this. Please contact your HT doctors and these companies working on low systemic delivery, spencer, etc etc and lets try to make this happen. **** CB and everything else that has not been proven. if we can deliver fin and cut to the follicles without systemic absorption, that's a huge victory for a whole lot of us. It will at least get us to the point in the future when better treatments arrive. It has already been shown by has son and wong that topical fin is better side effect wise than oral, and something that is specifically not meant to go systemic would be huge. CB might not even work, and wouldn't be out til 2018 anyway.

If this works, I'd get on fin/dut immediately and go for an HT and move the f**k on with my life.

[sdsurfin]

We really need to push this. Please contact your HT doctors and these companies working on low systemic delivery, spencer, etc etc and lets try to make this happen. **** CB and everything else that has not been proven. if we can deliver fin and cut to the follicles without systemic absorption, that's a huge victory for a whole lot of us. It will at least get us to the point in the future when better treatments arrive. It has already been shown by has son and wong that topical fin is better side effect wise than oral, and something that is specifically not meant to go systemic would be huge. CB might not even work, and wouldn't be out til 2018 anyway.

[balding1983]

I wonder if GSK and Merck are aware of companies like this. They can get rid of the stigma associated with both Propecia and Dutasteride with this technology. If only these companies could work together.

[thechamp]

I wonder if we made a cream lotion with this technology we could avoid systematic sides all together ?

[inbrugge]

Can we have this right away? Good grief I'm loosing like 20 hairs each time I scuffle my head. I need something right away. I'm so tempted to hop on Fin but it's gonna screw my body up. This sucks man.

BTW, no response from them for me. I sent them an e-mail a while back if you guys remember.

[thechamp]

A topical dut that only acted locally would really rock MPB but the question is does it absorb properly and how much still goes systemic? If the vehicle gets results with little systemic absorption than yeah it would really be a pretty big deal for maintaining hair safely

This is true for some one like me that gets weight gain with fin I wonder if I could avoid it going systematic and avoiding weight gain !

[burtandernie]

A topical dut that only acted locally would really rock MPB but the question is does it absorb properly and how much still goes systemic? If the vehicle gets results with little systemic absorption than yeah it would really be a pretty big deal for maintaining hair safely

[thechamp]

Let's start finding and emailing these companies we want answers buy the end of the week !!

[sdsurfin]

Completely agreed. This is really the best hope we have as far as maintenance. A low systemic fin or dut could be an absolute savior for all of us who can't take it in a pill. This whole forum should be knocking on these companies' doors. Also anyone who has had a hair transplant or has a hair doc should be bugging them to look into and promote this as well. I'm sure every ht surgeon would get more business if there were a reliable topical, and by the time cb comes out it'll be too late for many (if it even works) even if it does work, imagine what a combo of these topical a could do. Stem cell shit is way way off, let's focus on this.

[thechamp]

http://www.medscape.com/viewarticle/822505


looks like there is more than one company/person doing similar work....



DENVER — The topical TrkA kinase inhibitor CT327 reduces chronic itch in patients with psoriasis, according to results from a new study.

"This is an unmet need," said Gil Yosipovitch, MD, professor of dermatology at Temple University and the director of Temple Itch Center in Philadelphia.

"There are very few topical treatments that are targeted for chronic itch, and psoriasis has a significant component of itch that is not just related to the severity of the disease," he told Medscape Medical News.

Dr. Yosipovitch presented the research here at the American Academy of Dermatology 72nd Annual Meeting.

Unlike other topical medications that target inflammation, CT327 directly targets the itch. The drug is formulated with a technology called low systemic exposure, which prevents the inhibitor from getting past the upper layer of skin. This is important because TrkA inhibitors have been tested systemically in the past and can cause adverse effects, Dr. Yosipovitch explained.

His team conducted a phase 2b study of 160 patients with mild to moderate psoriasis who rated their itch on a visual analog scale.

Subjects had a Psoriasis Area and Severity Index score of around 9. Of the 95% of subjects who reported itch, the severity was at least moderate in 70% of patients and severe in 35%.

Let's contact these companies now , imagine if topical fin didn't go systematic blocking all the dht in the scalp it would be more effective than taking propecia get on to this

[ShookOnes]

http://www.neomatica.com/2014/09/07/skin-penetrating-ionic-liquids-synergize-antibiotics-efficient-microbial-killing/

[NeedHairASAP]

http://www.medscape.com/viewarticle/822505

looks like there is more than one company/person doing similar work....



DENVER — The topical TrkA kinase inhibitor CT327 reduces chronic itch in patients with psoriasis, according to results from a new study.

"This is an unmet need," said Gil Yosipovitch, MD, professor of dermatology at Temple University and the director of Temple Itch Center in Philadelphia.

"There are very few topical treatments that are targeted for chronic itch, and psoriasis has a significant component of itch that is not just related to the severity of the disease," he told Medscape Medical News.

Dr. Yosipovitch presented the research here at the American Academy of Dermatology 72nd Annual Meeting.

Unlike other topical medications that target inflammation, CT327 directly targets the itch. The drug is formulated with a technology called low systemic exposure, which prevents the inhibitor from getting past the upper layer of skin. This is important because TrkA inhibitors have been tested systemically in the past and can cause adverse effects, Dr. Yosipovitch explained.

His team conducted a phase 2b study of 160 patients with mild to moderate psoriasis who rated their itch on a visual analog scale.

Subjects had a Psoriasis Area and Severity Index score of around 9. Of the 95% of subjects who reported itch, the severity was at least moderate in 70% of patients and severe in 35%.

[FearTheLoss]

Arashi,

I actually just filled out the form on their "contact us" page. I'm assuming you emailed them at this address that is posted? bd@creabilis-sa.com

They say right on that page they are interested in other projects and partnerships, it would really be beneficial if a doctor or someone got on this. Hell, it could potentially be a product sold to masses that could make a lot of money if marketed properly, and of course, if it worked properly.

[clarence]

But dut and fun are pretty effective as maintenance options. If you then combine that with a fue, you're 'cured' as long as you are not beyond a nw5 of course.

I was hoping you'd say there is some added benefit with the topical version for all of us, who are already ok with the pill. Looks like the most promising short term solution for me... is a fue